Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.
Several studies have demonstrated that obesity can reduce survival in cancer patients. While definitive trials that include weight loss as an adjuvant intervention have not yet been conducted, several observational studies have evaluated the impact of this intervention on survival in women with breast and other cancers. Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.
The authors screened articles in PubMed and Web of Science, published between 2013 and July 2016. Of the total 311 publications identified, 10 were considered eligible for analysis—6 were in breast cancer survivors and 2 in endometrial cancer. Women were recruited to participated anytime between 9.4 months to up to 4 to 5 years following diagnosis. Interventions included diet and exercise, but the method of delivery and duration of the intervention varied. Interventions included:
Based on their analysis, the researchers found that while weight control and lifestyle changes are important in survivorship care, the biggest challenge is to maintain participant motivation and engagement at the end of the intervention to continue their weight-loss regimen. The other challenge with these studies, the authors wrote, is their “one-size-fits-all” approach with respect to intervention delivery, targets, and the content, which could make the intervention ineffective. The authors believe that researchers need to develop a more personalized approach to weight loss and lifestyle interventions.
Additional research conducted by these authors by mining ongoing trials, on ClinicalTrials.org and the International Standard Randomized Controlled Trial Number Registry, identified several ongoing randomized controlled clinical trials, which they believe “will potentially provide definitive assessment on whether weight loss can improve clinical outcome in female cancer survivors.”
Reference
Chlebowski RT, Reeves MM. Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol. 2016;34(35):4238-4248. doi: 10.1200/JCO.2016.69.4026.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More